Skip to content

Screening for Familial Gastric Cancer in first degree relatives

Screening for Familial Gastric Cancer in first degree relatives - FamGaCan

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON37219
Enrollment
100
Registered
2012-09-05
Start date
2012-11-05
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Familial Gastric Cancer

Interventions

None listed

Sponsors

Universitair Medisch Centrum Sint Radboud
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1] Adult from age of 18 years, female and male relatives 2] Fully legal competent (to simplify the common consent agreement for blood withdrawal, and serial endoscopies.) 3] Individuals that signed the common consent agreement 4] First degree relative of an individual with diffuse gastric cancer from a Familial Gastric Cancer-family: o OR: 2 or more individuals with diffuse gastric carcinoma, at least one

Exclusion criteria

Exclusion criteria: - immature individuals - actual gastric ulcer or gastric bleeding - previous diagnosis of cancer - individuals with co-morbidity which might increase the sedation and/or endoscopy risk: COPD Gold III/IV Cardiac failure Increased bleeding tendency or use of medication which increases bleeding tendency (and cannot be stopped temporarily)

Design outcomes

Primary

MeasureTime frame
The primary study outcome of this study is to determine if spraying of the gastric mucosa with acetic acid and Indigo carmine will increase the detection rate of these (pre)malignant lesions.

Secondary

MeasureTime frame
Secundary study paramers of this study are: A] To determine if standardized sampling, colouring and examination of the histological specimens will contribute to the detection of (pre-)malignant FDGC. B] To determine the optimal interval for endoscopic screening. C] To determine the contribution as well as association with clinical, life-style and dietary habits to the development of FGC. D] And finally, to determine the psychosocial impact of screening in individuals in this population.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)